The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo

Abstract

Vascular endothelial growth factor (VEGF) is known to occur as at least six differentially spliced variants, giving rise to mature isoforms containing 121, 145, 165, 183, 189 and 206 amino acids. However, little is yet known concerning the in vivo activities of this differential splicing. Stably transfected MCF-7 breast carcinoma cells were constructed that secreted comparable amounts of the 121, 165 or 189 isoforms. Rabbit corneal angiogenesis assays showed the VEGF121 transfectant to have much greater angiogenic activity than the 165 or 189 expressing MCF-7 cells. While the VEGF121-expressing MCF-7 cells were reproducibly more tumorigenic than the control transfectants, this was not the case with the VEGF165- or VEGF189-expressing cells. More surprising was the observation that VEGF189 located to the nucleus, consistent with the presence of a highly conserved nuclear localization sequence in exon 6a that is expressed in VEGF189 but not 121 or 165. It was concluded that the VEGF121 isoform is both more angiogenic and tumorigenic than are the 165 and 189 isoforms. This is probably due to the ability of the 121 isoform, unlike the 165 and 189 isoforms, to freely diffuse from the cells producing it.

References 23

1. 1.

   Acland P., Dixon M., Peters G., Dickson C. Subcellular fate of the int-2 oncoprotein is determined by choice of initiation codon. Nature. 1990;343(6259):662-665.

   Not in our library10.1038/343662a0

2. 2.

   Bader T., Weitzerbin J. Nuclear accumulation of interferon gamma. Proc Natl Acad Sci U S A. 1994;91(25):11831-11835.

   Not in our library10.1073/pnas.91.25.11831

3. 3.

   Carmeliet P., Ng Y. S., Nuyens D., Theilmeier G., Brusselmans K., Cornelissen I., Ehler E., Kakkar V. V., Stalmans I., Mattot V. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med. 1999;5(5):495-502.

   Not in our library10.1038/8379

4. 4.

   Cheung N., Wong M. P., Yuen S. T., Leung S. Y., Chung L. P. Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. Hum Pathol. 1998;29(9):910-914.

   Not in our library10.1016/s0046-8177(98)90195-2

5. 5.

   Coltrini D., Gualandris A., Nelli E. E., Parolini S., Molinari-Tosatti M. P., Quarto N., Ziche M., Giavazzi R., Presta M. Growth advantage and vascularization induced by basic fibroblast growth factor overexpression in endometrial HEC-1-B cells: an export-dependent mechanism of action. Cancer Res. 1995;55(20):4729-4738.

   Not in our library

6. 6.

   Gimbrone M. A., Cotran R. S., Leapman S. B., Folkman J. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst. 1974;52(2):413-427.

   Not in our library10.1093/jnci/52.2.413

7. 7.

   Gitay-Goren H., Cohen T., Tessler S., Soker S., Gengrinovitch S., Rockwell P., Klagsbrun M., Levi B. Z., Neufeld G. Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells. J Biol Chem. 1996;271(10):5519-5523.

   Not in our library10.1074/jbc.271.10.5519

8. 8.

   Grützkau A., Krüger-Krasagakes S., Baumeister H., Schwarz C., Kögel H., Welker P., Lippert U., Henz B. M., Möller A. Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell. 1998;9(4):875-884.

   Not in our library10.1091/mbc.9.4.875

9. 9.

   Houck K. A., Ferrara N., Winer J., Cachianes G., Li B., Leung D. W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. 1991;5(12):1806-1814.

   Not in our library10.1210/mend-5-12-1806

10. 10.

    Houck K. A., Leung D. W., Rowland A. M., Winer J., Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem. 1992;267(36):26031-26037.

    Not in our library

11. 11.

    Keyt B. A., Berleau L. T., Nguyen H. V., Chen H., Heinsohn H., Vandlen R., Ferrara N. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem. 1996;271(13):7788-7795.

    Not in our library10.1074/jbc.271.13.7788

12. 12.

    Lei J., Jiang A., Pei D. Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183. Biochim Biophys Acta. 1998;1443(3):400-406.

    Not in our library10.1016/s0167-4781(98)00240-1

13. 13.

    Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13(1):9-22.

    Not in our library

14. 14.

    Park J. E., Keller G. A., Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell. 1993;4(12):1317-1326.

    Not in our library10.1091/mbc.4.12.1317

15. 15.

    Relf M., LeJeune S., Scott P. A., Fox S., Smith K., Leek R., Moghaddam A., Whitehouse R., Bicknell R., Harris A. L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997;57(5):963-969.

    Not in our library

16. 16.

    Robbins J., Dilworth S. M., Laskey R. A., Dingwall C. Two interdependent basic domains in nucleoplasmin nuclear targeting sequence: identification of a class of bipartite nuclear targeting sequence. Cell. 1991;64(3):615-623.

    Not in our library10.1016/0092-8674(91)90245-t

17. 17.

    Siemeister G., Schnurr B., Mohrs K., Schächtele C., Marmé D., Martiny-Baron G. Expression of biologically active isoforms of the tumor angiogenesis factor VEGF in Escherichia coli. Biochem Biophys Res Commun. 1996;222(2):249-255.

    Not in our library10.1006/bbrc.1996.0730

18. 18.

    Smith K., Houlbrook S., Greenall M., Carmichael J., Harris A. L. Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene. 1993;8(4):933-938.

    Not in our library

19. 19.

    Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J. C., Abraham J. A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 1991;266(18):11947-11954.

    Not in our library

20. 20.

    Turley H., Scott P. A., Watts V. M., Bicknell R., Harris A. L., Gatter K. C. Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol. 1998;186(3):313-318.

    Not in our library10.1002/(sici)1096-9896(1998110)186:3<313::aid-path188>3.0.co;2-x

21. 21.

    Zhang H. T., Craft P., Scott P. A., Ziche M., Weich H. A., Harris A. L., Bicknell R. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst. 1995;87(3):213-219.

    Not in our library10.1093/jnci/87.3.213

22. 22.

    Ziche M., Morbidelli L., Choudhuri R., Zhang H. T., Donnini S., Granger H. J., Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest. 1997;99(11):2625-2634.

    Not in our library10.1172/jci119451

23. 23.

    Ziche M., Morbidelli L., Masini E., Amerini S., Granger H. J., Maggi C. A., Geppetti P., Ledda F. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest. 1994;94(5):2036-2044.

    Not in our library10.1172/jci117557

Cited by papers we hold 1

• Genetic and Pharmacologic Inhibition of Complement Impairs Endothelial Cell Function and Ablates Ovarian Cancer Neovascularization · 2012
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.